I. Nalbantgil et al., SUSTAINED-RELEASE VERAPAMIL AND TRANDOLAPRIL, ALONE AND IN COMBINATION, IN THE TREATMENT OF OBESE HYPERTENSIVE PATIENTS - A DOUBLE-BLIND PILOT-STUDY, Current therapeutic research, 57(12), 1996, pp. 990-997
Citations number
21
Categorie Soggetti
Pharmacology & Pharmacy","Medicine, Research & Experimental
The purpose of this pilot study was to compare the ability of sustaine
d-release verapamil (verapamil SR) and trandolapril, both alone and co
mbined in half doses, to reduce blood pressure in obese patients with
mild-to-moderate essential hypertension. Twenty patients (13 men and 7
women) took part in the study. Ten (group A) received verapamil SR 24
0 mg/d, and 10 (group B) received trandolapril 2 mg/d for 6 weeks. All
patients were then given both drugs in half-doses for 6 weeks. After
combination therapy, group B received verapamil SR 240 mg/d, and group
A received trandolapril 2 mg/d for 6 weeks. When verapamil and trando
lapril were used alone, systolic and diastolic blood pressures decreas
ed significantly in each group. However, systolic and diastolic blood
pressures fell further when combination therapy was used and rose slig
htly when the treatment was changed again to single-drug therapy. Side
effects were fewer during the combination therapy. Thus the combinati
on of half doses of verapamil SR and trandolapril was more effective i
n reducing blood pressure in obese patients with mild-to-moderate esse
ntial hypertension than a full dose of either drug given alone.